Literature DB >> 34671867

Immunosuppression and Heart Transplantation.

Nilay Sutaria1, Lynne Sylvia1, David DeNofrio2.   

Abstract

Since the first human heart transplant in 1967, immense advancements have been made in the field of immunosuppression. This chapter provides an in-depth analysis of the use of immunosuppressive agents in heart transplant recipients. Evidence regarding maintenance immunosuppressive regimens, the efficacy of induction immunosuppression and corticosteroid weaning, as well as the use of distinct immunosuppression regimens within select patient populations is summarized. This chapter helps elucidate the data regarding contemporary protocols in cardiac transplantation.
© 2021. Springer Nature Switzerland AG.

Entities:  

Keywords:  Azathioprine; Calcineurin inhibitors; Cancer; Cardiac; Corticosteroid; Cyclosporine; Everolimus; Heart; Immune; Immunosuppression; Induction; Maintenance; Mycophenolate; Orthotopic; Prednisone; Rejection; Sirolimus; Steroid; Tacrolimus; Transplant; Vasculopathy; mTOR inhibitors

Mesh：

Substances：

Year:  2022        PMID： 34671867     DOI： 10.1007/164_2021_552

Source DB:  PubMed          Journal:  Handb Exp Pharmacol        ISSN： 0171-2004


  46 in total

1.  Effects of mTOR inhibitor-related proteinuria on progression of cardiac allograft vasculopathy and outcomes among heart transplant recipients.

Authors:  Rabea Asleh; Hilmi Alnsasra; Amir Lerman; Alexandros Briasoulis; Naveen L Pereira; Brooks S Edwards; Takumi Toya; John M Stulak; Alfredo L Clavell; Richard C Daly; Sudhir S Kushwaha
Journal:  Am J Transplant       Date:  2020-07-21       Impact factor: 8.086

2.  Effect of everolimus introduction on cardiac allograft vasculopathy--results of a randomized, multicenter trial.

Authors:  Satish Arora; Thor Ueland; Bertil Wennerblom; Vilborg Sigurdadottir; Hans Eiskjær; Hans E Bøtker; Bjorn Ekmehag; Kjell Jansson; Svend-Aage Mortensen; Kari Saunamaki; Svein Simonsen; Einar Gude; Bjørn Bendz; Dag Solbu; Pål Aukrust; Lars Gullestad
Journal:  Transplantation       Date:  2011-07-27       Impact factor: 4.939

3.  Long-Term Sirolimus for Primary Immunosuppression in Heart Transplant Recipients.

Authors:  Rabea Asleh; Alexandros Briasoulis; Walter K Kremers; Rosalyn Adigun; Barry A Boilson; Naveen L Pereira; Brooks S Edwards; Alfredo L Clavell; John A Schirger; Richard J Rodeheffer; Robert P Frantz; Lyle D Joyce; Simon Maltais; John M Stulak; Richard C Daly; Jonella Tilford; Woong-Gil Choi; Amir Lerman; Sudhir S Kushwaha
Journal:  J Am Coll Cardiol       Date:  2018-02-13       Impact factor: 24.094

4.  Everolimus initiation and early calcineurin inhibitor withdrawal in heart transplant recipients: a randomized trial.

Authors:  A K Andreassen; B Andersson; F Gustafsson; H Eiskjaer; G Radegran; E Gude; K Jansson; D Solbu; V Sigurdardottir; S Arora; G Dellgren; L Gullestad
Journal:  Am J Transplant       Date:  2014-08       Impact factor: 8.086

5.  Induction immunosuppressive therapy in cardiac transplantation: a systematic review and meta-analysis.

Authors:  Alexandros Briasoulis; Chakradhari Inampudi; Mohan Pala; Rabea Asleh; Paulino Alvarez; Jay Bhama
Journal:  Heart Fail Rev       Date:  2018-09       Impact factor: 4.214

6.  A prospective, randomized trial of single-drug versus dual-drug immunosuppression in heart transplantation: the tacrolimus in combination, tacrolimus alone compared (TICTAC) trial.

Authors:  David A Baran; Mark J Zucker; Luis H Arroyo; Margarita Camacho; Marc E Goldschmidt; Stephen J Nicholls; Jeanne Prevost-Fernandez; Candace Carr; Laura Adams; Susan Pardi; Vera Hou; Maria Binetti; Jeanine McCahill; Joanne Chichetti; Valerie Viloria; Mary Gladys Sanagustin; Jennifer Ebuenga-Smith; Leslie Mele; Anthony Martin; Donna Blicharz; Kathy Wolski; Ludmilla Olesnicky; Fang Qian; Alan L Gass; Marc Cohen
Journal:  Circ Heart Fail       Date:  2011-01-07       Impact factor: 8.790

7.  Effect of Everolimus Initiation and Calcineurin Inhibitor Elimination on Cardiac Allograft Vasculopathy in De Novo Heart Transplant Recipients.

Authors:  Satish Arora; Arne K Andreassen; Kristjan Karason; Finn Gustafsson; Hans Eiskjær; Hans Erik Bøtker; Göran Rådegran; Einar Gude; Dan Ioanes; Dag Solbu; Göran Dellgren; Thor Ueland; Pål Aukrust; Lars Gullestad
Journal:  Circ Heart Fail       Date:  2018-09       Impact factor: 8.790

8.  Randomized trial of tacrolimus monotherapy: tacrolimus in combination, tacrolimus alone compared (the TICTAC trial).

Authors:  David A Baran; Mark J Zucker; Luis H Arroyo; Mamata M Alwarshetty; Maria R Ramirez; Thomas W Prendergast; Daniel J Goldstein; Margarita Camacho; Alan L Gass; Candace Carr; Marc Cohen
Journal:  J Heart Lung Transplant       Date:  2007-10       Impact factor: 10.247

9.  Everolimus Initiation With Early Calcineurin Inhibitor Withdrawal in De Novo Heart Transplant Recipients: Three-Year Results From the Randomized SCHEDULE Study.

Authors:  A K Andreassen; B Andersson; F Gustafsson; H Eiskjaer; G Rådegran; E Gude; K Jansson; D Solbu; K Karason; S Arora; G Dellgren; L Gullestad
Journal:  Am J Transplant       Date:  2016-01-28       Impact factor: 8.086

10.  The first human heart transplant and further advances in cardiac transplantation at Groote Schuur Hospital and the University of Cape Town - with reference to : the operation. A human cardiac transplant : an interim report of a successful operation performed at Groote Schuur Hospital, Cape Town.

Authors:  J G Brink; J Hassoulas
Journal:  Cardiovasc J Afr       Date:  2009 Jan-Feb       Impact factor: 1.167
View more
  1 in total

1.  Neutrophil to Lymphocyte Ratio (NLR) as an Easily Accessible Parameter for Monitoring Tacrolimus Overdose after Heart Transplantation-Experimental Study.

Authors:  Tomasz Urbanowicz; Anna Olasińska-Wiśniewska; Michał Michalak; Michał Rodzki; Anna Witkowska; Ewa Straburzyńska-Migaj; Bartłomiej Perek; Marek Jemielity
Journal:  Diagnostics (Basel)       Date:  2021-12-24
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.